Mezion "American Heart Association Recognizes 'FUEL Clinical Trial' for Advancing Congenital Heart Disease Last Year"
[Asia Economy Reporter Hyunseok Yoo] Mezzion announced on the 10th that the American Heart Association (AHA) recognized the Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL) clinical study last year as the research that made the greatest contribution to the advancement of congenital heart disease.
A company official explained, "The AHA, which is the world's largest funder of heart and heart failure research, recognized the FUEL clinical trial, which confirmed the improvement of exercise capacity with udenafil in patients with single ventricle disease, published in the journal 'Circulation,' as the most meaningful and contributory study in 2019."
Since 1996, the AHA has compiled a list of major advancements related to heart and heart failure every year. According to the company, Mezzion's FUEL clinical trial was selected as one of the most successful trials among groups divided into 10 different fields last year.
A company representative said, "We are very encouraged that Mezzion's FUEL clinical trial was selected by the AHA as the most contributory research in the congenital heart disease category in 2019," adding, "This recognition from the AHA highlighted Mezzion's pioneering development using udenafil to treat Fontan patients and its dedication to the single ventricle patient community."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "Insisting on Phone Consultations Only for Hearing-Impaired Clients"... Human Rights Commission Recommends Staff Training for Foundation
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Mezzion also emphasized that the National Heart, Lung, and Blood Institute (NHLBI), an agency under the U.S. National Institutes of Health, recognized the FUEL clinical trial's contribution to the advancement of congenital heart disease in 2019. In the January issue of the journal 'Advancing Heart, Lung, Blood, and Sleep Research,' NHLBI stated, "As a result of the FUEL clinical trial, treatment with udenafil, a drug that improves blood circulation, significantly enhanced the ability of adolescent Fontan patients to maintain appropriate exercise levels."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
